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Abstract
Biofilms are surface-attached bacterial communities embedded within an extracellular matrix that create
localized and protected microenvironments. Acidogenic oral biofilms can demineralize the enamel-apatite
on teeth, causing dental caries (tooth decay). Current antimicrobials have low efficacy and do not target
the protective matrix and acidic pH within the biofilm. Recently, catalytic nanoparticles were shown to
disrupt biofilms but lacked a stabilizing coating required for clinical applications. Here, we report dextrancoated iron oxide nanoparticles termed nanozymes (Dex-NZM) that display strong catalytic (peroxidaselike) activity at acidic pH values, target biofilms with high specificity, and prevent severe caries without
impacting surrounding oral tissues in vivo. Nanoparticle formulations were synthesized with dextran
coatings (molecular weights from 1.5 to 40 kDa were used), and their catalytic performance and
bioactivity were assessed. We found that 10 kDa dextran coating provided maximal catalytic activity,
biofilm uptake, and antibiofilm properties. Surprisingly, dextran coating also enhanced selectivity toward
biofilms while avoiding binding to gingival cells. Mechanistic studies indicated that iron oxide cores were
the source of catalytic activity, whereas dextran on the nanoparticle surface provided stability without
blocking catalysis. Dextran-coating facilitated NZM incorporation into exopolysaccharides (EPS) structure
and binding within biofilms, which activated hydrogen peroxide (H2O2) for localized bacterial killing and
EPS-matrix breakdown. In combination with low concentration of H2O2, Dex-NZM inhibited biofilm
accumulation on natural teeth in a human-derived ex vivo biofilm model, and prevented acid damage of
the mineralized tissue. Furthermore, Dex-NZM/H2O2 treatment significantly reduced the onset and
severity of caries lesions (vs control or either Dex-NZM or H2O2 alone) without adverse effects on gingival
tissues or oral microbiota diversity in vivo. Therefore, dextran-coated nanozymes have potential as an
alternative treatment of a prevalent and costly biofilm-induced oral disease.
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ABSTRACT
Dextran-coated Iron Oxide Nanoparticles as Biomimetic Catalysts for
Biofilm Disruption and Caries Prevention
Yuan Liu
Hyun (Michel) Koo, DDS, PhD
Biofilms are surface-attached bacterial communities embedded within an extracellular matrix that
create localized and protected microenvironments. Acidogenic oral biofilms can demineralize the
enamel-apatite on teeth, causing dental caries (tooth decay). Current antimicrobials have low
efficacy and do not target the protective matrix and acidic pH within the biofilm. Recently,
catalytic nanoparticles were shown to disrupt biofilms but lacked a stabilizing coating required for
clinical applications. Here, we report dextran-coated iron oxide nanoparticles termed nanozymes
(Dex-NZM) that display strong catalytic (peroxidase-like) activity at acidic pH values, target
biofilms with high specificity, and prevent severe caries without impacting surrounding oral tissues
in vivo. Nanoparticle formulations were synthesized with dextran coatings (molecular weights
from 1.5 to 40 kDa were used), and their catalytic performance and bioactivity were assessed. We
found that 10 kDa dextran coating provided maximal catalytic activity, biofilm uptake, and
antibiofilm properties. Surprisingly, dextran coating also enhanced selectivity toward biofilms
while avoiding binding to gingival cells. Mechanistic studies indicated that iron oxide cores were
the source of catalytic activity, whereas dextran on the nanoparticle surface provided stability
without

blocking

catalysis.

Dextran-coating

facilitated

NZM

incorporation

into

exopolysaccharides (EPS) structure and binding within biofilms, which activated hydrogen
peroxide (H2O2) for localized bacterial killing and EPS-matrix breakdown. In combination with
low concentration of H2O2, Dex-NZM inhibited biofilm accumulation on natural teeth in a humanderived ex vivo biofilm model, and prevented acid damage of the mineralized tissue. Furthermore,

Dex-NZM/H2O2 treatment significantly reduced the onset and severity of caries lesions (vs control
or either Dex-NZM or H2O2 alone) without adverse effects on gingival tissues or oral microbiota
diversity in vivo. Therefore, dextran-coated nanozymes have potential as an alternative treatment
of a prevalent and costly biofilm-induced oral disease.
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CHAPTER 1: INTRODUCTION
1.1 Oral biofilms: More than Just a Cluster of Bacteria
Many infectious diseases are caused or exacerbated by biofilms1-3. Oral infectious diseases are
prime examples of the consequences of dynamic interactions between microorganisms, their host,
and the host’s diet, leading to microbial colonization of oral surfaces and the establishment of
pathogenic biofilms (or dental plaque)1,4. Biofilms are defined as structured communities of
microorganisms that are attached to a surface and enmeshed in an extracellular polymeric matrix1.
Advances in DNA- and RNA-sequencing technologies are revealing important information about
the diversity in composition, genome content, and behaviors of the biofilm microbiota at different
oral sites1. There are many factors that affect the composition of the microbiota found on various
surfaces of the mouth, especially when teeth begin to erupt, providing novel, nonshedding surfaces
for colonization by commensals and opportunistic pathogens. These include, but are not limited
to, age, diet, oral hygiene, systemic and immune conditions, and the use of certain medications
that induce, for example, hyposalivation. The critical role that diet plays in microbial colonization
is well illustrated in patients or experimental animals5,6. When hosts are overexposed to dietary
sugars, the structure and composition of biofilms formed on teeth changes significantly and the
residing microbial communities become highly fit to metabolize carbohydrates and produce acids
leading to dental caries7.
Although early studies focused on microbial composition of biofilms, it is now clear that
microorganisms residing within biofilms are embedded in a matrix containing extracellular
polymeric substances such as exopolysaccharides (EPS). The importance of the matrix in the
collective microbial behavior and virulence, as well as for tolerance of antimicrobials, is being

increasingly recognized and considered integral to the biofilm lifestyle2,3,8. EPS production
directly mediates microbial adherence to a surface and cell-to-cell adhesion, while forming a
polymeric matrix that enhances mechanical stability of biofilms. Furthermore, the diffusionmodifying properties of EPS matrix cause chemical/nutrient gradients to form, thereby creating
microenvironments within biofilms that can vary widely from other sites in key environmental
inputs known to affect microbial behaviors, including pH, redox, and nutrient availability. Thus,
the matrix allows the cells to organize into cohesive multicellular ecosystems where cooperative
and antagonistic interactions occur within a heterogeneous chemical and physical milieu2, helping
to create localized niches with differing pathogenic potentials.
1.2 The Cariogenic Biofilm and Its Complex Biochemical Microenvironment
Dental caries is a classic biofilm-induced disease that causes the destruction of the mineralized
tooth tissue7,9,10. The microorganisms in the oral cavity are required, but not sufficient, to cause
dental caries because the formation of cariogenic biofilms is dependent on the host diet1,7,11. In the
mouth, the microbial interactions start with early colonizers that can rapidly adhere to the pelliclecoated tooth surface and then co-adhere with other microorganisms. During this process, the
various species interact physically and metabolically to shape the initial biofilm community
structure. Certain interactions are beneficial as commensals (e.g., Streptococcus gordonii and
Streptococcus salivarius) can compete against cariogenic bacteria (e.g., Streptococcus mutans) by
secreting hydrogen peroxide and bacteriocins as “chemical weapons” or counter the deleterious
effects of acidification by producing alkali11-13. However, the dynamic balance between
commensals and pathogens can be disrupted by frequent sugar consumption and poor oral care,
which promotes the development of virulent biofilms in close proximity to the tooth surface
(Figure 1).

A diet rich in sugars fuels the assembly of the EPS matrix and enhances accumulation of
acidogenic and acid-tolerant microbiota9,10, which can explain microscopic images of plaquebiofilms collected from caries active sites, revealing bacteria enmeshed in EPS (Figure 2). S.
mutans, a member of the mutans streptococci (MS) group, has long been implicated with dental
caries in human. Extensive clinical, epidemiological, and experimental animal studies have shown,
conclusively, though not exclusively, that MS are strongly associated with the disease, especially
early childhood caries (ECC)14. One of the primary adaptations that allow S. mutans to become
such an efficient opportunistic pathogen within the oral microbiota resides with its exceptional
capacity to use a wide variety of carbohydrates to produce EPS and acids, and to live a biofilm
lifestyle, including stress resistance and bacterial competence mechanisms1,9,10. One sugar in
particular, sucrose, is most cariogenic as the component hexose (glucose and fructose) provide the
building blocks of EPS and are efficiently fermented to produce acids1. When sucrose is available,
EPS-producing exoenzymes such as S. mutans-derived glucosyltransferases (Gtfs) present in the
pellicle and also bound to different microorganisms (including commensal streptococci,

Actinomyces spp., Candida albicans) produce large amounts of glucans in situ15,16. The surfaceformed EPS provide avid binding sites for adhesion and co-adhesion that promote mixed-species
biofilm formation17. EPS then accumulates to form a complex polymeric 3D matrix scaffold in
which microorganisms become enmeshed and assemble highly organized and compartmentalized
3D biofilm architecture8,15,18.

Biophysical analysis of biofilms and EPS are clarifying their physical contributions to local
microenvironments and resistance to mechanical removal and antimicrobials. Well-established
biofilms are mechanically difficult to remove from the surfaces and often display viscoelastic
properties, which can help them persist by partially yielding rather than detaching when subject to
external (fluid) shear stresses19,20. EPS deposition on surfaces and development into polymeric
matrix affect the mechanical properties of biofilms, such as increasing adhesive strength to
surfaces and coadhesiveness19. Matrix stiffness appears to increase as the biofilm matures20. The
physicochemical properties of the biofilm matrix can also provide protection to embedded bacteria

by reducing drug access and triggering antimicrobial tolerance. For example, the EPS can bind
cationic antimicrobials, such as chlorhexidine and antimicrobial peptides, preventing penetration
into the deeper layers of the biofilm, and thereby reducing killing efficacy21,22.

In the context of dental caries, how and where acidic microenvironments are formed, maintained,
and protected within the 3D biofilm architecture may be the key determinant because the buffering
saliva surrounding the tooth surfaces is capable of neutralizing acids produced in the mouth. The
heterogeneous spatial distribution of pH across oral biofilm structures has been long appreciated9.

A fluorescent pH indicator, directly incorporated into the biofilm matrix, revealed a fascinating
3D pH distribution within intact biofilms despite exposure to neutral pH buffer22. Localized low
pH environments (4.5-5.5) were detected in the interior of the EPS-microcolony complexes and at
the biofilm-apatite interface suggesting that the acids accumulated and confined in these specific
areas are not readily neutralized (Figure 3). The EPS matrix has been shown to limit diffusion of
charged ions in buffers, whereas uncharged solutes, such as sucrose, can diffuse into biofilms and
can be rapidly metabolized into acids by the embedded bacteria23. Furthermore, extracellular
glucans appear to directly trap protons to help retain and accumulate acids within biofilms 24. The
biofilm matrix can also act as an external digestion system by immobilizing exoenzymes, allowing
them to metabolize substrates in close proximity to cells while also participating in matrix
remodeling. For instance, soluble fructans and glucans present in the matrix can be degraded by
fructanase and dextranase, providing readily fermentable carbohydrates on-site and thereby
extending the duration of the acid challenge15. Thus, EPS can modulate persistent acidification at
the tooth interface by helping biofilms to adhere, spatially localize metabolites, and possibly
restrict access to buffering saliva, which helps to create a cariogenic microenvironment.
1.3 Challenges and Limitations of Current Antimicrobial Approaches
Despite significant advances in the prevention of dental caries, particularly with the use of fluoride,
controlling cariogenic biofilms remains challenging. Major hurdles include the following: 1)
microorganisms within biofilms are enmeshed and protected in an EPS-rich matrix, making them
difficult to kill or remove; 2) EPS-embedded microbes create highly acidic microenvironments
that promote cariogenic biofilm buildup and reduce drug efficacy; and 3) topically applied agents
are poorly retained on teeth or within biofilms due to rapid clearance in the mouth. Hence,
therapeutic approaches against cariogenic biofilms that could both disrupt the matrix and

simultaneously kill the bacteria within biofilms with enhanced retention and efficacy at acidic pH
values would be desirable.
Current approaches against cariogenic biofilms are mostly limited to conventional, broadspectrum antimicrobials that are incapable of degrading the protective matrix or affecting the
physicochemical aspects of dental caries. Although capable of killing planktonic bacteria and
reducing microbial accumulation on teeth, chlorhexidine is far less effective against established
biofilms, does not prevent caries, and is not suitable for daily use due to adverse effects, including
calculus formation and tooth staining25. Likewise, hydrogen peroxide (H2O2), a readily available
antiseptic agent, also has antimicrobial effects yet limited activity on biofilms even at high
concentrations (>3%). Thus, antimicrobials have limited efficacy for caries prevention or treatment
if not combined with other modalities. Furthermore, frequent use of broad-spectrum antimicrobials
may potentially cause ecological imbalance, increasing susceptibility to reinfection by
opportunistic pathogens, including S. mutans24. Nevertheless, when conditions are not conducive
for dental caries, currently available antimicrobials (including essential oils) can help maintain
biofilm accumulation to levels compatible with a healthy mouth26.
Conversely, fluoride is currently the mainstay of caries prevention27, but it does not offer complete
protection28. Fluoride exerts its major effect by enhancing remineralization and reducing tooth
enamel demineralization but has limited effects against biofilms despite inhibiting bacterial
metabolism29. Alternatively, EPS-degrading enzymes like dextranase and mutanase can digest
biofilm EPS matrix30 but have no antibacterial activity and limited clinical efficacy when used
alone in addition to practical issues, including high cost, immunogenicity and low enzyme
stability. Furthermore, natural products have shown multiple biological effects, including
antibacterial, antiadhesion, and glucan synthesis inhibition, many of which demonstrated

promising therapeutic effects using in vivo caries models31. However, it is a challenging approach
owing to complex chemistry and composition variability of natural products as well as multistep
isolation procedures to derive active compounds, although advances in analytical/chemical
separation methods may mitigate these limitations.
Nanomaterials have received increased attention for biofilm control and caries prevention through
intrinsic antibacterial properties, as a carrier to deliver bioactive molecules or even as
remineralizing agents such as calcium phosphate nanostructures32,33. However, most antibacterial
nanomaterials are designed to inhibit bacterial adhesion rather than disrupting existing biofilm.
Moreover, these materials are not designed to break down the biofilm matrix or to specifically
target the pathological microenvironments found in cariogenic biofilms (with few exceptions).
Therefore, new approaches for enhanced anticaries effects should eradicate biofilms locally and,
at the same time, prevent acid dissolution of the adjacent tooth enamel.
1.4 New Therapeutic Approaches for Biofilm Control
While our understanding of biofilm microenvironments is evolving, technological advances are
providing unprecedented avenues to develop multi-targeted therapeutic approaches that prevent
and disrupt biofilms or enhance drug efficacy. Nano- and chemical engineering approaches
provide unparalleled flexibility to control the composition, size, shape, surface area and surface
chemistry, and functionality of nanostructures that can be used to develop a new generation of
modified materials or to coat existing solid surfaces to prevent the formation of biofilms (Figure
4). Functionalized nanoparticles, including stimuli-triggered activation, can be designed to
enhance penetration and selectively target or release drugs locally after bacterial attachment or
within biofilms. For example, nanoparticles can be used to coat existing surfaces (e.g., teeth) and
exogenously introduced surfaces (e.g., restorative or implant materials) for prevention of bacterial

adhesion and cariogenic biofilm formation34. Specifically, functionalized nanoparticles can be
conceived to carry and selectively release or activate antimicrobial agents at the surface of
attachment or within oral biofilms. The latter mechanism includes “smart release or activation” of
agents when triggered by pathogenic microenvironments (e.g., acidic pH) that could
simultaneously kill bacteria and dismantle the biofilm matrix. Recently, functional polymeric

nanostructures (PNs) were developed for enhanced drug delivery when triggered by acidic pH
values35. These nanostructures are formed from diblock copolymers and 2-propylacrylic acid that
self-assemble into cationic nanoparticles. By tuning the PNs’ outer corona surface, they display
outstanding adsorption affinities to pellicle and EPS-coated apatitic surfaces due to strong
electrostatic interaction35. Owing to hydrophobic cores, these “nanocarriers” can encapsulate

nonpolar antibacterial drugs such as farnesol with high efficiency while making them soluble in
aqueous solution due to hydrophilic outer corona. With this specific polymer conjugation, the
nanoparticles undergo core destabilization and drug release in a pH-responsive manner, triggered
by the acidification of the biofilm microenvironment in cariogenic conditions. These pH-activated
polymeric nanocarriers enhanced the antibiofilm activity of farnesol by 4-fold (vs. free farnesol),
significantly improving its efficacy against caries severity in vivo (>10-fold) under twice-daily
topical treatment regimen.
Iron oxide nanoparticles have been widely used as contrast agents in MRI because of their high
biocompatibility and ability to penetrate tumor and atherosclerotic plaque, resulting in many FDAapproved formulations36. Interestingly, the iron oxide nanoparticles display an intriguing
biomimetic activity by displaying enzyme-like (peroxidase) activity, and thereby have been termed
nanocatalyts or nanozymes. In a seminal work, Gao et al.37 demonstrated that iron oxide

nanoenzyme (NZM) possess an intrinsic peroxidase-like activity, which enable them to catalyze
the breakdown of H2O2, and rapid production of bioactive free radicals (Figure 5). Hydrogen
peroxide (H2O2) is a commonly used low cost antiseptic for general disinfection purposes or as
tooth-whitening agent (at concentrations as high as 10%) because it generates free radicals that
exhibit antibacterial activity or stain removal (through degradation of polymeric substances).
However, the process is slow and H2O2 by itself has modest anti-biofilm or endodontic disinfection
effects when used alone. The catalytic nanoparticles could potentiate the efficacy of hydrogen
peroxide by enhancing the production of free radicals locally for improved antibacterial effects.
Recently, this concept was proven successful to kill bacterial embedded within biofilms using
short-term topical applications with exceptional efficacy (5,000 times more effective than H2O2
alone)37. However, for clinical applications, NZM require coatings as uncoated nanoparticles lack
stability in physiological media and in solutions suitable for therapeutic formulations and can bind
to biological tissues indiscriminately, which could lead to adverse effects to healthy tissues38,39.
Ideally, the presence of coatings would improve biofilm targeting and maintain catalytic activity,
while enhancing biocompatibility, which could result in a more practical and specific anti-biofilm
treatment.
In this study, we hypothesized that dextran-coated NZM (Dex-NZM) could be incorporated into
biofilms while maintaining its intrinsic catalytic activity to break down the EPS structure and kill
bacteria upon exposure to H2O2 at cariogenic (acidic) pH values. In addition, dextran coating
would also result in stability in aqueous formulations and enhanced biofilm targeting specificity,
providing biocompatibility to the host soft tissue in the oral cavity.

CHAPTER 2: MATERIALS AND METHODS
2.1 Synthesis of Dextran-Coated NZM (Dex-NZM)
A range of Dex-NZM formulations were synthesized based on a protocol published elsewhere40,41,
using varying dextran molecular weights (from 1.5 to 40 kDa). In brief, 12.5 g of dextran
(Pharmacosmos, Holbaek, Denmark) of the selected molecular weight was dissolved in 25 mL of
deionized (DI) water. Once the dextran completely dissolved in DI water, the solution was placed
in an ice bath and purged with nitrogen gas to remove oxygen from the ﬂask. A 0.985 g portion of
ferric chloride hexahydrate and 0.366 g of ferrous chloride tetrahydrate (Sigma-Aldrich, St. Louis,
MO) were each dissolved in 6.25 mL of DI water separately and then added to the dextran solution.
The reaction mixture was allowed to stir for 45 min at 4°C for complete mixing of iron salts with
dextran solution. Next, 15 mL of ammonium hydroxide (28−30%, Sigma-Aldrich) was added to
the reaction mixture using a syringe pump. The ammonium hydroxide was added to the reaction
mixture at diﬀerent rates, i.e., 0.3 μL/min for the ﬁrst 2.5 h and then 0.6, 0.9, and 1.2 μL/min for 1
h each consecutively. The remainder of the ammonium hydroxide was added to the reaction
mixture at a rate of 4 μL/min. After the addition of ammonium hydroxide was completed, the
reaction mixture was heated to 90°C for 1 h and then stirred overnight at room temperature. The
nanoparticle suspension was then spun at 20,000 g for 30 min at 4°C, after which the supernatant
was collected and concentrated using ultraﬁltration tubes (molecular weight cut oﬀ 100 kDa,
Sartorius Stedim Biotech, Germany). The concentrated Dex-NZM was puriﬁed with citrate buﬀer
via diaﬁltration columns (100 kDa, Spectrum Labs, CA). After puriﬁcation, Dex-NZM was stored
at 4°C. Conjugation with Alexa 488 NHS Ester (ThermoFisher Scientiﬁc) was achieved by
introducing amine groups to the dextran coating, as previously described41, and then following the
manufacturer’s instructions. These ﬂuorescent nanoparticles were further puriﬁed using

ultraﬁltration tubes (molecular weight cut oﬀ 100 kDa, Sartorius Stedim Biotech). UV−vis
(Evolution 201 UV−vis spectrophotometer, ThermoFisher Scientiﬁc) and ﬂuorescence spectra
(SpectraMax, M5, Molecular Devices) proved that Alexa-488 was conjugated successfully to the
nanoparticle surface (Figure 6). Uncoated NZM were synthesized by ﬁrst dissolving 1.1 g of ferric
chloride hexahydrate and 0.4 g of ferrous chloride tetrahydrate (Sigma-Aldrich) in 15 mL of DI
water each and then transferring these solutions to a three-necked ﬂask. The reaction mixture was
stirred under an inert nitrogen atmosphere. The reaction mixture was heated to 85°C, and then 20
mL of diluted ammonium hydroxide solution (2.5 mL of 28% ammonium hydroxide diluted to 20
mL with DI water) was added dropwise to the reaction mixture. After addition of ammonium
hydroxide, the reaction mixture was stirred at 85°C for 1 h. Next, the nanoparticles were collected
magnetically and were puriﬁed with DI water using diaﬁltration columns (100 kDa)42.

2.2. Characterization of Dex-NZM
Hydrodynamic Diameter and Zeta Potential. The hydrodynamic diameter and zeta potential of
each Dex-NZM were measured using a Nano-ZS 90 (Malvern Instrument, Malvern, UK). Then

1.5 and 1 mL of diluted Dex-NZM (12.5 μL Dex-NZM stock solution to 1 mL of DI water) were
used for the hydrodynamic diameter and zeta potential measurements, respectively.
Transmission Electron Microscopy. Transmission electron microscopy (TEM) of each Dex-NZM
was performed using a JEOL 1010 microscope operating at 80 kV. Then 5 μL of nanoparticle
suspension was dropped onto the TEM grid (FCF-200-Cu, Electron Microscopy Sciences,
Hatﬁeld, PA), and the liquid was allowed to dry before microscopy was performed.
Inductively Coupled Plasma Optical Emission Spectroscopy. The iron concentration in each DexNZM formulation was measured using inductively coupled plasma optical emission spectroscopy
(ICP-OES)41. Then 5, 10, or 25 μL of Dex-NZM was dissolved in 1 mL of aqua regia. After
complete dissolution of Dex-NZM, the ﬁnal volume in each tube was adjusted to 10 mL with DI
water. The iron concentration was measured using ICP-OES (Spectro Genesis ICP). The
concentration obtained from the ICP-OES was adjusted by the dilution factor for each sample and
then averaged to determine the iron concentration in the stock solution. The total amount of iron
within intact bioﬁlms (i.e., bacterial cells and EPS combined) was also measured using ICP-OES.
Bioﬁlms treated with Dex-NZM formulations were transferred to glass tubes and digested with 1
mL of aqua regia overnight at room temperature. Then the volume was adjusted to 10 mL with DI
water prior to analysis with ICP-OES37,41. Three independent experiments were performed for each
Dex-NZM formulation, and the data are presented as mean ± SD.
Catalytic Activity (TMB) Assay. The peroxidase-like catalytic activities of the Dex-NZM
formulations were investigated via a colorimetric assay using 3,3,5,5-tetramethylbenzidine (TMB,
Sigma Aldrich) and hydrogen peroxide (H2O2) following a previously published protocol37, with
a slight modiﬁcation. This assay is well established as an assessment of peroxidase-like
activity43,44, where H2O2 and the TMB substrate are converted to water and an oxidized form of

TMB that is blue in color. UV measurements at 652 nm allow the oxidation of TMB to be
monitored and catalytic activity to be compared. The catalytic activity of each Dex-NZM was
measured at three diﬀerent pH values, i.e., 4.5, 5.5, and 6.5. The assay was performed in 96-well
plates. A 300 μL portion of 0.1 M sodium acetate (NaOAc) buﬀer at the appropriate pH was added
to each well of a 96-well plate. Then, 1.2 μL of Dex-NZM (5 mg Fe/mL) was added to the wells.
After the addition of Dex-NZM, 3 μL TMB (10 mg/mL) and 15 μL of H2O2 (0.5% v/v) were added
to each well and mixed vigorously. After addition of hydrogen peroxide, the 96 well plate was
immediately placed into a plate reader, and the absorbance was recorded at 652 nm at 1 min
intervals for 30 min. Three independent experiments were performed for each Dex-NZM
formulation. The slope of the line was calculated and averaged, and the data are presented as mean
± SD.
Iron Release and Catalytic Activity of Released Iron Ions. The eﬀect of iron ion release from 10
kDa Dex-NZM was studied in 0.1 M NaOAc buﬀer (pH 4.5). A 1 mL portion of Dex-NZM (5 mg
Fe/ml) was diluted with 9 mL of 0.1 M NaOAc buﬀer. After mixing, samples were incubated at
37°C for 5, 30, 60, and 120 min (n = 3 per time point). After the desired incubation time, the free
iron ions and nanoparticles were separated using ultraﬁltration tubes (10 kDa MWCO). The iron
content in the ﬁltrate and the nanoparticle pellet from each incubation time point were measured
using ICP-OES. The catalytic activity of the released iron in the supernatant and nanoparticle pellet
from each incubation time point was analyzed using the TMB assay, as described above. Three
independent experiments were performed per incubation time point, and the data are presented as
mean ± SD.
Dex-NZM Binding to Saliva-Coated Hydroxyapatite Beads. In this binding assay, 10 mg of salivacoated HA beads was incubated in 500 μL of Dex-NZM solution at a concentration of 0.2 mg/mL

for 30 min with rocking at 37°C. Then the supernatant was removed, and the beads were washed
three times with water to remove unbound nanoparticles. The beads were dissolved with 1 mL of
70% HNO3, and the iron was analyzed via ICP-OES41.
2.3 Bacterial Killing and EPS Degradation by Dex-NZM activated H2O2
Time-lapse high-resolution confocal fluorescence imaging was performed to assess the dynamics
of bacterial killing and glucan structure breakdown Streptococcus mutans UA159 (ATCC
700610), a virulent cariogenic pathogen and well-characterized biofilm-forming strain, was grown
in ultra-filtered (10-kDa cutoff; Millipore) tryptone-yeast extract (UFTYE) broth at 37°C and 5%
CO2 to mid-exponential phase. Dex-NZM was added to actively growing S. mutans (108 CFU/mL)
at a concentration of 1 mg/mL in the presence of 1% H2O2 at pH 4.5 or pH 6.5. SYTO 60 (652/678
nm; Molecular Probes) and propidium iodide (PI, 535/617 nm; Molecular Probes) were used for
labelling live and dead cells. In addition, we conjugated Dex-NZM with Alexa Fluor 488 (490/525
nm; Molecular Probes) to visualize nanoparticle binding and localization on the cell surface.
Confocal images were acquired in the same field of view at 0, 10, 20, 30, and 40 min using Zeiss
LSM800 upright single photon laser scanning microscope with a 40 × (numerical aperture, 1.2)
water immersion objective. Images were analyzed by ImageJ. For EPS degradation, insoluble
glucans were produced by purified S. mutans-derived exoenzyme glucosyltransferase B (GtfB)
immobilized on poly-L-lysine coated MatTek dish and labelled with 1 μM Alexa Fluor 647dextran conjugate (647/668 nm; Molecular Probes) as described previously45. The preformed
fluorescently labelled glucans were then incubated with Dex-NZM (1 mg/mL) and 1% H2O2 (in
0.1 M NaOAc buffer at pH 4.5 or 6.5), and time-lapsed confocal imaging was performed as
described above using a 20 × (numerical aperture, 1.0) water immersion objective. To further
examine the glucan degradation process, we also employed computational analysis (Amira and

ImageJ) that generates structural scaffold based on geometrical and topological properties of the
EPS, including length and width45.
2.4 Oral Biofilm Model
Bioﬁlms were formed on saliva-coated hydroxyapatite (sHA) disks (surface area, 2.7 ± 0.2 cm2,
Clarkson Chromatography Products Inc., South Williamsport, PA), as described elsewhere22,37,
that were vertically suspended in 24-well plates. Streptococcus mutans UA159 (ATCC 700610)
was grown in ultraﬁltered (10 kDa molecular-mass cutoﬀ) tryptone-yeast extract broth (UFTYE;
2.5% tryptone and 1.5% yeast extract) containing 1% (w/v) glucose at 37°C and 5% CO2 to midexponential phase. Each HA disk was coated with ﬁlter-sterilized saliva for 1 h at 37°C (the saliva
was prepared as described previously)22,37. These sHA disks were each inoculated with ∼2 × 105
colony forming units (CFU) of S. mutans per milliliter in UFTYE culture medium (pH 7.0)
containing 1% (w/v) sucrose at 37°C. The culture medium was changed twice daily (at 19 and 29
h) until the end of the experimental period (43 h). The bioﬁlms were collected and analyzed for
Dex-NZM binding and catalytic activity as well as bioactivity as described below.
Bacterial Killing and Biomass Reduction by Dex-NZM with H2O2. To assess the antibioﬁlm eﬀect
of Dex-NZM bound within bioﬁlms, the sHA disks and bioﬁlms were topically treated twice daily
by placing them in 2.8 mL of Dex-NZM (0.5 mg/mL) in 0.1 M NaOAc (pH 4.5) or vehicle control
(buﬀer only) for 10 min at room temperature at speciﬁc time points (Figure 7). At the end of the
experiment (43 h), the Dex-NZM- and vehicle-treated bioﬁlms were placed in 2.8 mL of H2O2
(1%, v/v or buﬀer) for 5 min. After H2O2 exposure, the bioﬁlms were washed with sterile saline
solution (0.89% NaCl) three times. The bioﬁlms were then removed by a spatula from sHA discs
and homogenized via bath sonication followed by probe sonication35,37,46. Samples of these bioﬁlm
suspensions were serially diluted and plated onto blood agar plates using an automated EddyJet

Spiral Plater (IUL, SA, Barcelona, Spain). The numbers of viable cells in each bioﬁlm were
calculated by counting CFU. The remaining suspension was centrifuged at 5,500 g for 10 min, the
resulting cell pellets were washed twice with water, oven-dried for 2 h, and weighed35,37,46.

Catalytic Activity within Intact Bioﬁlm. The catalytic activity of 10 kDa Dex-NZM within intact
bioﬁlms was measured after incubations similar to those described above. Bioﬁlms grown on sHA
disks were treated twice daily by placing them in 2.8 mL of Dex-NZM (0.5 mg/mL) in 0.1 M
NaOAc (pH 4.5) or vehicle control (buﬀer only) for 10 min at room temperature at speciﬁc time
points (Figure 7)37. At the end of the experimental period (43 h), all the bioﬁlms were washed with
0.1 M NaOAc buﬀer (pH 4.5) three times and transferred to the reaction buﬀer (500 μL 0.1 M
NaOAc, pH 4.5 containing 1% H2O2 and 100 μg TMB). The reaction was allowed to proceed for
30 min at room temperature without shaking. After the reaction, still images of intact bioﬁlms were
acquired, and subsequently, the bioﬁlms were removed using a spatula from the disk surfaces and
centrifuged at 5,500 g for 10 min. Then the absorbance from the supernatant was recorded at 652
nm. Three independent experiments were performed, and the data are presented as mean ± SD.
Distribution of Dex-NZM within Bioﬁlm Architecture. Confocal ﬂuorescence imaging was
performed using an upright microscope (LSM 800, Zeiss) with a 20 × (numerical aperture, 1.0)
water immersion objective to assess the distribution of Dex-NZM, dynamics of bacterial killing,
and EPS degradation within bioﬁlm. Dex-NZM conjugated with Alexa Fluor 488, prepared as

described above, was used. SYTO 82 (541/560 nm; Molecular Probes) was used for labeling
bacteria, and Alexa Fluor 647-dextran conjugate (647/668 nm; Molecular Probes) was used for
labeling insoluble EPS. Each component was illuminated sequentially to minimize cross-talk as
follows: Alexa 488 (Dex-NZM) was excited using 488 nm and was collected by a 480/40 nm
emission ﬁlter; SYTO 82 (bacterial cells) was excited using 560 nm, and was collected by a 560/40
nm emission ﬁlter; Alexa 647 (EPS) was excited using 640 nm and was collected by a 670/40 nm
emission ﬁlter. To assess colocalization of Dex-NZM with bacteria or EPS, each channel was
processed with Otsu’s thresholding method using ImageJ.
2.5 Human-derived Ex Vivo Biofilm Model on Natural Teeth
To further assess the antibiofilm efficacy of Dex-NZM-mediated H2O2 catalysis, we examined
whether daily topical treatments can disrupt cariogenic biofilm development and prevent enamel
surface damage using an ex vivo biofilm model. Plaque-biofilm samples were collected from
children (age between 36 and 72 months) diagnosed with severe early childhood caries (S-ECC)
as defined by the 2014 Conference Manual of the American Academy of Pediatric Dentistry.
Ethical approval of the study and the written consent/permission forms were obtained from
Institutional Review Board (IRB) at University of Pennsylvania (IRB 824243) prior to the study
commencement. For each child, written permission form was reviewed and signed by their legal
guardians. Pooled plaque samples were collected from the available smooth tooth surfaces using
a sterilized periodontal scaler and transferred into 1 mL phosphate-buffered saline (PBS) in a
sterilized Eppendorf tube. After collection, the plaque samples were immediately transported on
ice to the laboratory, and then gently vortexed and sonicated (three 10 s pulses with 30 s intervals
at 7 W) to disperse the aggregates before inoculation47,48. Different pooled samples were checked
for S. mutans, which is frequently found in high numbers in cariogenic plaque-biofilm associated

with S-ECC14, and total cultivable bacteria to ensure similar S. mutans proportion for the inoculum.
The human-derived ex vivo biofilms were formed on sterilized human enamel blocks (4 mm × 4
mm) mounted vertically in 24-well plates using a custom-made wire holder (Figure 8). Each
enamel block was inoculated with homogenized pooled plaque in UFTYE containing 1% sucrose
at 37°C and 5% CO2 for 115 h (5 d) as described previously22. To mimic topical treatment regimen,
the enamel blocks and biofilms were topically treated twice-daily by placing them in 2.8 ml of
Dex-NZM (1 mg/mL) in 0.1 M NaOAc (pH 4.5) for 10 min immediately followed by 1% H2O2
exposure for 5 min. After each treatment, the biofilms were dip-washed with 0.89% NaCl and
transferred to fresh culture medium. Biofilm were removed at 115 h for three-dimensional (3D)
structural analysis and the enamel blocks were collected for surface analysis via surface
topography, roughness measurement and transversal microradiography48,49.

Analysis of Ex Vivo Derived Biofilm. The biofilms formed on enamel blocks were gently washed
twice with PBS and fixed with 4% paraformaldehyde (in PBS, pH7.4) at 4°C for 4 h. After fixation,
the biofilms were washed twice with PBS, then transferred into 50% ethanol (in PBS, pH 7.4) and
stored at −20°C. The biofilm 3D architecture was analyzed via fluorescence in situ hybridization
(FISH) as detailed previously48-51. FISH oligonucleotide probes used in this study were: EUB338,

5’-GCTGCTCCCGTAGGATG-3’

with

Cy3

for

all

bacteria;

Smu587,

5’-

ACTCCAGACTTTCCTGAC-3’ with Alexa Fluor 488 for S. mutans. The sample in the
hybridization buffer (30% formamide, 0.9 M NaCl, 0.01% sodium-dodecylsulphate (SDS), 20 mM
Tris-HCl, pH 7.2) with the probes was incubated at 46°C for 2 h. After incubation, the hybridized
cells were washed with washing buffer (0.2 M NaCl, 20 mM Tris-HCl (pH 7.5) and 5 mM EDTA,
0.01% SDS), and further incubated at 46°C for 10 min48-51. The EPS were labeled with 1 μM Alexa
Fluor 647-dextran conjugate (647/668 nm; Molecular Probes)22. The 3D biofilm architecture was
acquired using Zeiss LSM 800 with a 20 × (numerical aperture, 1.0) water immersion objective.
The biofilms were sequentially scanned using diode lasers (488, 561, and 640 nm), and the
fluorescence emitted was collected with GaAsP or multialkali PMT detector (475–525 nm for
Alexa Fluor 488, 540–580 nm for Cy3, and 645–680 nm for Alexa Fluor 647-dextran conjugates,
respectively). Amira 5.4.1 software (Visage Imaging) was used to create 3D renderings to visualize
the architecture of the biofilms.
Enamel Surface Analyses. The surface topography and roughness of the tooth-enamel surface
(after biofilm removal) were analyzed by a nondestructive confocal contrasting method using Zeiss
LSM 800 with a C Epiplan-Apochromat 50 × (numerical aperture, 0.95) nonimmersion objective.
The images were processed using ConfoMap (Zeiss) to create 3D topography rendering and
measure the surfaces properties in 3D. After surface analyses, enamel blocks were mounted on
plastic rods and sectioned with a hard tissue microtome (Silverstone-Taylor Hard Tissue
Microtome, Series 1000 Deluxe) for transversal microradiography. One 100 μm section was
obtained from the center of each specimen, mounted on X-ray sensitive plates (Microchrome
Technology) and subjected to X-ray, along with an aluminum step wedge. Microradiographic

images were analyzed with Inspektor TMR 2000 software (ver. 1.25) with sound enamel defined
at 87% mineral volume to obtain mean lesion depth (μm)49.
2.6 In Vivo Rodent Model of Severe Childhood Caries
The therapeutic efficacy of Dex-NZM-mediated H2O2 catalysis were assessed on a wellestablished rodent caries model as detailed elsewhere35,52. Briefly, 15 days-old female Sprague–
Dawley rat pups were purchased with their dams from Harlan Laboratories (Madison). Upon
arrival, animals were screened for S. mutans and were determined not to be infected with the
pathogen by plating oral swabs on mitis salivarius agar plus bacitracin. The animals were then
infected by mouth with actively growing (mid-logarithmic) culture of S. mutans UA159, and their
infections were confirmed at 21 days via oral swabbing. To simulate clinical situation, we
developed a combination therapy consisting of 1 min topical treatment of Dex-NZM at 1 mg/mL
(or buffer) immediately followed by 1% H2O2 (or buffer) exposure. All the pups (equal numbers)
were randomly placed into treatment groups, and their teeth were treated topically twice daily
using a custom-made applicator (Figure 9)35,37. The treatment groups were: (1) control (0.1 M
NaOAc buﬀer, pH 4.5), (2) Dex-NZM only (1 mg/mL), (3) 1% H2O2 only, and (4) Dex-NZM/H2O2
(1 mg/mL Dex-NZM with 1% H2O2). The treatments were blinded by placing the test agents in
color-coded vials. Each group was provided the National Institutes of Health cariogenic diet 2000
and 5% sucrose water ad libitum. The experiment proceeded for 3 weeks (21 days). All animals
were weighed weekly, and their physical appearances were noted daily. At the end of the
experimental period, the animals were sacrificed, and the jaws were surgically removed and
aseptically dissected, followed by sonication to recover total oral microbiota53. All jaws were
defleshed and the teeth were prepared for caries scoring according to Larson’s modification of
Keyes’system35,37,52. Determination of caries score of the jaws was performed by a calibrated

examiner who was blind for the study by using codified samples. Furthermore, both gingival and
palatal tissues were collected and processed for hematoxylin and eosin (HE) staining for
histopathological analysis by an oral pathologist at Penn Oral Pathology. This study was reviewed
and approved by the University of Pennsylvania Institutional Animal Care and Use Committee
(IACUC #805529).

16S rRNA Gene Amplicon Sequencing. Dispersed oral microbiota samples were eluted in PBS with
cell lysis buffer from a DNeasy kit (Qiagen) as described by the manufacturer. After a 60 s vortex,
DNA present in the buffer was isolated with the DNeasy Power Soil HTP kit and quantitated with
a spectrophotometer (Tecan). The 27F/338R primer with Golay-barcode in the reverse primer was
used to amplify the V1–V2 region of 16S ribosomal DNA (16S rDNA; IDT). Four replicate PCR
reactions were performed for each sample using Q5 Hot Start High Fidelity DNA Polymerase
(New England BioLabs). Each PCR reaction contained: 4.3 μL microbial DNA-free water, 5 μL 5
× buffer, 0.5 μL dNTPs (10 mM), 0.17 μL Q5 Hot Start Polymerase, 6.25 μL each primer (2 μM),
and 2.5 μL DNA. PCR reactions without template or with synthetic DNAs were performed as
negative and positive controls, respectively. PCR amplification was done on a Mastercycler Nexus
Gradient (Eppendorf) using the following conditions: DNA denaturation at 98°C for 1 min, then
20 cycles of denaturation 98°C for 10 s, annealing 56°C for 20 s and extension 72°C for 20 s, last

extension at 72°C for 8 min. PCR replicates were pooled and then purified using a 1:1 ratio of
Agencourt AMPure XP beads (Beckman Coulter), following the manufacturer’s protocol. The
final library was prepared by pooling 10 μg of amplified DNA per sample. Those that did not reach
at the DNA concentration threshold (e.g., negative control samples) were incorporated to the final
pool by adding 12 μL. The library was sequenced to obtain 2 × 250 bp paired-end reads using the
MiSeq Illumina54. Sequence data was analyzed with the QIIME pipeline (ver. 1.9.1)54. The forward
and reverse reads were joined with no mismatches permitted. Read quality lower than Q29 or more
than 3 consecutive low-quality base calls were discarded. Sequences were clustered into
operational taxonomic units (OTU) at a 97% similarity threshold using the UCLUST method55.
Taxonomic assignments were obtained based on GreenGenes16S rRNA gene database56. To test
the differences between communities, library vegan, and Unifrac distances were used57,58.
Diversity, richness, and bacterial taxon abundances were compared using the Wilcoxon rank sum
test. Principle coordinate analysis (PCoA) was performed using library APE for R programming
language59.
2.7 Cell Viability
The cytotoxicity of each Dex-NZM formulation was evaluated in primary human gingival
epithelial cells (HGECs) and human ﬁbroblast (BJ-5ta) cells using the MTS [(3-(4,5dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)]

assay

(CellTiter 96 cell proliferation assay kit; Promega, WI, USA)60. HGECs were a gift from Dr.
Manju Benakanakere (School of Dental Medicine, University of Pennsylvania), and BJ-5ta cells
were purchased from ATCC (Manassas, VA, USA). HGECs were cultured in keratinocyte serumfree medium (Invitrogen, NY)61. BJ-5ta cells were cultured in a 4:1 mixture of Dulbecco’s
Modiﬁed Eagle’s Medium (DMEM) and medium 199, supplemented with 10% fetal bovine serum

(Gibco, NY) and 0.01 mg/mL of hygromycin B (Sigma-Aldrich). The assay was performed in 96well plates; 10,000 cells in 100 μL of cell culture media were added to each well, and then the
plates were incubated at 37°C in a 5% CO2 atmosphere for 24 h. After this time, the cells were
washed gently with sterile phosphate buﬀered saline (PBS) before 100 μL of Dex-NZM or
uncoated NZM (0.5 mg Fe/mL) in cell culture medium was added to the wells. The plates were
then incubated at 37°C in 5% CO2 atmosphere for 10 min. After this incubation, the media was
removed, the cells were washed with PBS, and then 20 μL MTS reagent and 100 μL cell culture
medium were added to each well. The plates were then incubated at 37°C in a 5% CO2 atmosphere
for 1 h, after which time the absorbance was recorded at 490 nm using a plate reader. For the 24 h
cell viability experiment, the cell culture medium with Dex-NZM was removed from each well
after 10 min of incubation. Then the cells were washed with PBS, 100 μL of fresh cell culture
medium was added to each well, and the plates incubated for a further 24 h. The MTS reagents
were then added, and the absorbance was recorded at 490 nm (as described above). Three
independent experiments were performed for each Dex-NZM formulation. The percentage of cell
viability was calculated, and the results were presented as mean ± SD.
2.8 Statistical Analysis
All the results are presented as mean ± SD. Data were analyzed using one-way analysis of variance
(ANOVA) with post-hoc Tukey HSD test for multiple comparison. A pairwise comparison was
conducted using Student’s t test. Differences between groups were considered statistically
significant when P < 0.05. Statistical analyses were performed using SPSS version18.0 software.
2.9 Ethics Statement
The animal experiment was conducted in strict accordance with the guidelines of the Animal
Welfare Act of the United States, under the protocol reviewed and approved by the Institutional

Animal Care and Use Committee of the University of Pennsylvania (IACUC#805529). The
plaque-biofilm samples collection from S-ECC children were approved by Institutional Review
Board (IRB) at University of Pennsylvania (IRB 824243) and were used only for the sole purpose
of biofilm formation on enamel surfaces. The written permission form for each child was reviewed
and signed by their legal guardians. The whole saliva is a convenient sample (with no identifiers)
collected for the sole purpose of coating the hydroxyapatite discs for the in vitro biofilm studies.
All adult subjects provided written informed consent (no children participated in the saliva
collection) under the protocol reviewed and approved by the University of Pennsylvania Research
Subject committee (IRB#818549).

CHAPTER 3: RESULTS
In this study, we developed Dex-NZM for the treatment of bioﬁlms associated with dental caries.
Since dextran is a FDA approved polymer, and dextran-coated iron oxide nanoparticles such as
Feridex and Ferumoxytol, have been FDA-approved and used for magnetic resonance imaging36,62
and treating iron deficiency anemia63, we hypothesized that the presence of a dextran coating on
the nanoparticle surface could enhance bioﬁlm targeting speciﬁcity and biocompatibility without
signiﬁcantly impacting the catalytic activity of the iron oxide core43,64,65. We tested several
different formulations that were synthesized using different dextran molecular weights and found
that 10 kDa Dex-NZM provided an optimal balance of catalytic activity, bioﬁlm uptake, and when
exposed to low H2O2 concentration, resulted in marked bacterial killing and bioﬁlm reduction,
preventing caries severity without adverse effects in vivo.
3.1 Dextran-Coated NZM Maintain Catalytic Activity
Dex-NZM formulations were synthesized using a range of dextran molecular weights since we
sought to understand the effect of the molecular weight of the coating on catalytic activity, bioﬁlm
incorporation, and antibioﬁlm effects. TEM of Dex-NZM formulations revealed that nanoparticles
were formed in each case (Figure 10a). The core sizes of Dex-NZM coated with 1.5, 5, 10, 25, and
40 kDa dextran are 32.5 ± 14.2, 14.7 ± 3, 11.4 ± 1.8, 15.6 ± 3.6, and 32.2 ± 9.6 nm, respectively.
The iron oxide cores formed with 5, 10, and 25 kDa dextran were similar in morphology, whereas
very heterogeneous iron oxide cores were formed when 1.5 and 40 kDa dextran was used. The
hydrodynamic diameters of these Dex-NZM formulations range from 30 to 60 nm, without a clear
correlation with dextran molecular weight (Figure 10b). Unsurprisingly, their zeta potentials were
similar, all being slightly negative, consistent with other reports for dextran-coated iron oxide
nanoparticles (Figure 10b)66. The peroxidase-like activities of Dex-NZM were measured using the

colorimetric TMB assay. These experiments were done at pH 4.5, 5.5, and 6.5 to span the range
of pH values expected to exert catalytic activity. Stronger catalytic activities were observed at
more acidic pH, i.e., 4.5 (found in cariogenic bioﬁlms7,67) compared to pH 6.5 (noncariogenic) for
all formulations, indicating that damage caused by reduction of hydrogen peroxide and consequent
generation of reactive oxygen species would be higher against pathological bioﬁlms (Figure 10c).
Interestingly, the highest catalytic activity was observed for the 10 kDa dextran formulation, which
is likely due to it having the smallest core size and thus highest surface area.

To determine whether Dex-NZM were taken up in bioﬁlms, we performed topical treatments using
an established saliva-coated hydroxyapatite (pellicle-coated tooth mimetics) bioﬁlm model under
cariogenic conditions using the oral pathogen S. mutans grown in the presence of sucrose (Figure
7). We found that these nanoparticles were retained within bioﬁlms when applied topically and

that 10 kDa Dex-NZM was taken up to the greatest extent as determined by ICP-OES (Figure 10d).
We also examined whether the activation of H2O2 by Dex-NZM is due to catalytic activity from
nanoparticles themselves or from released iron ions via the Fenton reaction. We found only trace
amounts of free iron ions leached from Dex-NZM in acidic pH buffer (pH 4.5, Figure 10e).
Importantly, the catalytic activity of the solution phase is low (Figure 10f), showing that the
observed activity is primarily derived from the nanoparticle itself. Furthermore, the
biocompatibilities of Dex-NZM formulations were tested with human primary oral gingival cells
and human fibroblast cells. We found that none of the Dex-NZM formulations inhibited the
viability of either cell type when incubated at a concentration of 0.5 mg of iron/mL (Figure 10g,h).
When selecting which formulation to pursue for further in-depth studies, i.e., analysis of catalytic
activity, binding speciﬁcity, bacterial killing, EPS degradation, ex vivo biofilm prevention and in
vivo testing, we chose the 10 kDa dextran formulation since it has the highest catalytic activity and
biofilm uptake. Moreover, the FDA approved dextran-coated iron oxide nanoparticle uses 10 kDa
dextran36, further motivating more detailed study of this formulation and its use for in vivo eﬃcacy
evaluation.
3.2 Dextran Coating Inﬂuences on Catalytic Activity, Stability, and NZM Bioﬁlm Binding
To further understand the behavior of Dex-NZM, we performed additional studies to assess
catalytic performance and bioactivity in detail, including the role of dextran (vs uncoated NZM)
on bioﬁlm uptake and incorporation into bioﬁlm structure via EPS. We compared the catalytic
activity of Dex-NZM and uncoated NZM of similar core size to Dex-NZM and found that the
dextran coating reduced activity somewhat, in line with results found by others64 (Figure 11a).
Furthermore, the activity of dextran alone was very low and, when dextran was mixed with
uncoated NZM at the concentration found in Dex-NZM (5.4:1 dextran to iron mass ratio), there

was not a statistically signiﬁcant diﬀerence in activity compared with uncoated NZM alone.
Therefore, dextran coatings do not contribute to catalytic activity, but allow reagents to access iron
oxide cores so that catalytic activity occurs. Furthermore, we found that Dex-NZM was
catalytically active within a cariogenic bioﬁlm (Figure 11b).

Given that dextran coating could enhance dispersibility and exogenous dextran can be incorporated
into EPS matrix22,68, we hypothesized that Dex-NZM could display improved formulation stability
and binding speciﬁcity toward bioﬁlms rather than mammalian tissues or uncolonized tooth
surfaces. In order to probe this question, we used the aforementioned uncoated NZM as a
comparator. The Dex-NZM was stable and did not settle in any of the media tested, underscoring
the potential clinical utility and commercial potential of this agent (settling in storage could result
in uneven dosing to the subject). We found that Dex-NZM is well suspended in water, PBS, and
saliva (Figure 11c), but uncoated NZM are not stable in PBS and saliva as evidenced by settling
to the bottom of the vial when suspended in PBS or saliva (at 1 h) and even in DI water (at 24 h).
Next, we tested the selectivity of uncoated and dextran-coated NZM. Excitingly, we found that
Dex-NZM was unable to bind to mammalian cells (both oral gingival and ﬁbroblast cells), whereas
uncoated NZM bound very strongly and in high amounts, as evidenced by ICP-OES measurements
(Figure 11d). On the other hand, Dex-NZM and uncoated NZM were both taken up in bioﬁlms
signiﬁcantly (Figure 11e).

We further examined the uptake of these nanoparticles in bioﬁlms by testing their incorporation
into EPS formed on hydroxyapatite surfaces via the action of GftB. Dex-NZM were incorporated
into EPS to a much greater extent than uncoated NZM (Figure 11f), likely due to Dex-NZM’s

chemical similarity to dextran, which can be incorporated into the EPS structure during glucan
synthesis by S. mutans-derived GtfB exoenzymes via acceptor reaction22. Moreover, we examined
the binding of these nanoparticles to saliva coated hydroxyapatite (sHA) as a tooth surface mimetic
and observed that Dex-NZM had much lower binding to the apatitic surface than uncoated NZM
(Figure 11g). Thus, we unexpectedly found that while Dex-NZM were taken up by bioﬁlms, they
were unable to bind to mammalian cells and less avidly to sHA, while uncoated iron oxides were
bound to all tested surfaces, highlighting the selectivity of Dex-NZM toward bioﬁlms.

3.3 In Vitro Bioactivity of Dex-NZM
The Dex-NZM activation of H2O2 indicated that it could, therefore, function as a bacterial killing
and EPS degrading system for targeting the acidic biofilm microenvironment. To assess the

bioactivity of Dex-NZM-mediated H2O2 catalysis, we conducted high-resolution time-lapsed
imaging using fluorescently labelled bacterial cells (S. mutans) and insoluble α-glucans (Figure
12). Dex-NZM (1 mg/mL) was added to an actively growing bacterial cells suspension followed
by exposure to H2O2 at a concentration of 1%, under acidic (4.5) or near neutral pH (6.5)
conditions. To visually observe the distribution of viable and dead bacteria, intact S. mutans cells
were labelled with SYTO 60 and propidium iodide (PI) was used to determine bacterial killing
over time at the single-cell level. The fluorescence images show that S. mutans viability was
affected as early as10 min by Dex-NZM in the presence of H2O2 at pH 4.5. Bacterial cells are
labelled in blue by SYTO 60 and the purple color indicates dead cells labelled by PI, a cellimpermeant molecule that can only enter cells with damaged membranes, rapidly gaining
intracellular access following treatment (Figure 12a). In addition, close-up views of individual
bacterial cells with high magnification show Dex-NZM (labelled with Alexa Fluor 488, in yellow)
located on the cell surface (Figure 12b, c).
Insoluble glucans are key virulence factors as they form the core of the extracellular matrix in
cariogenic biofilms1. Thus, we also assessed whether these EPS can be broken down following
incubation with Dex-NZM and H2O2. The EPS were labelled by Alexa Fluor 647-dextran
conjugate during glucan synthesis as detailed previously22, allowing structure visualization and
degradation monitoring via time-lapse imaging. As shown in Figure 12d, the glucans (in red) were
readily degraded when exposed to Dex-NZM and H2O2 in acidic pH. To further understand the
EPS breakdown process over time, we applied computational analysis that generates geometrical
scaffolds based on connectivity, topology, and length of the glucan structure. Intact glucans show
a web-like structure, forming a meshwork of interwoven “EPS filaments” (Figure 12d, blue lines).
However, after exposure to Dex-NZM and H2O2, we observed gradual dismantling of the matrix

structure by degrading the interconnected branches (see white arrowheads), resulting in a smaller
EPS core with most of the shorter fragments completely degraded after 40 min (Figure 12d). These
results indicate efficient bacterial killing with EPS degrading capabilities when Dex-NZMmediated H2O2 catalysis is triggered at acidic pH.

3.4. Antibiofilm Activity of Dex-NZM
To further assess the Dex-NZM binding and antibioﬁlm activity, we employed high-resolution
confocal ﬂuorescence imaging combined with quantitative computational analysis. Alexa-488
conjugated Dex-NZM was employed to visualize the nanoparticle distribution within bioﬁlm
architecture. Representative confocal images show Dex-NZM (labeled in green) associated with
the entire bacterial cluster (in gray) and also incorporated throughout the EPS matrix (in purple)
structure (Figure 13a-d). This was confirmed by energy dispersive spectroscopy (EDS), where Fe
signals was found in the EDS spectra of Dex-NZM-treated biofilm (Figure 13e), additionally
illustrating the successful incorporation of Dex-NZM into biofilms following topical treatment.
Considering the effective Dex-NZM binding and catalytic activity within biofilms, we investigated
whether the bound nanoparticles could catalyze H2O2 to breakdown the EPS matrix and kill the

embedded bacteria in situ. We found that the numbers of dead bacteria (in red) markedly increased
(Figure 13g, h), and concurrently, the EPS matrix (in purple) was degraded (Figure 13i, k),
indicating antibioﬁlm eﬀects in situ via the catalytic activity of Dex-NZM. To further confirm the
bioactivity of Dex-NZM, the number of viable cells and EPS content were determined in the
treated biofilms. The results show potent biocidal activity against S. mutans within biofilm,
causing > 6-log reduction of viable cells compared to vehicle control and > 1000-fold more
effective than H2O2 alone (Figure 13l, P < 0.01–0.001 by paired t test).

Importantly, the treatment

significantly reduced the amount of insoluble glucans compared to control and to H2O2 or DexNZM alone, further indicating the EPS-degrading capability of Dex-NZM-mediated H2O2
catalysis (Figure 13m, P < 0.001 by paired t test).

3.5 Disruption of Ex Vivo Biofilms and Human Enamel Demineralization
We next developed a combination therapy consisting of topical application of Dex-NZM (at 1
mg/mL) immediately followed by H2O2 (at 1%) exposure, twice daily to simulate oral use. To gain

further insight into the therapeutic potential of our approach, we used an ex vivo human biofilm
model to assess whether Dex-NZM/H2O2 can disrupt cariogenic biofilm and prevent enamel
surface damage. In this model, plaque-biofilm samples were collected from diseased patients
affected by severe childhood caries and inoculated for biofilm development on natural human
tooth-enamel (Figure 8). The microscale spatial distribution and structural organization of the
biofilm components were determined via a multi-labeling approach using total bacteria and S.
mutans specific fluorescent probes, with EPS-matrix labeling via an Alexa Fluor 647-dextran
conjugate. The control human-derived biofilms had ‘dome-shaped’ bacterial clusters (in blue)
spatially arranged with EPS (in red) matrix (Figure 14a) that are typically found when grown under
cariogenic conditions in the presence of sucrose. Cross-sectional confocal images reveal localized
bacterial aggregates comprised mostly of S. mutans cells (in green, Figure 14a bacteria panel) that
are surrounded by an interconnected EPS-matrix (in red, Figure 14a EPS panel) forming cohesive
and densely packed microbial structure. In a sharp contrast, only small cell clusters with sparsely
distributed EPS were detected in the Dex-NZM/H2O2 treatment group (Figure 14b).
The striking differences in both bacterial density and structural organization could inflict
differential damage of the mineralized tooth tissue underneath the distinctive biofilms.
Macroscopically, we observed large areas of enamel surface demineralization in the control group;
close-up views show chalky and white spot-like demineralization, similar to early caries lesions
seen clinically (Figure 14c). In contrast, the enamel surface from Dex-NZM/H2O2 treatment was
essentially devoid of such opaque demineralized areas (Figure 14e). The observed visual
differences were confirmed with confocal topography imaging and transversal microradiography
analysis. The enamel surfaces from the control group have eroded forming microcavities resulting
in ~10 times higher surface roughness (Sa values) than that treated with Dex-NZM/H2O2, whose

enamel surface was mostly intact and smooth (Figure 14g, h). Importantly, the lesion depth as
determined by microradiography is significantly deeper in the control group (vs. Dex-NZM/H2O2
group, Figure 14d, f, P < 0.01 by paired t test).

Altogether, the in vitro data demonstrate bioﬁlm targeting speciﬁcity by Dex-NZM, which in turn
can effectively kill bacterial cells and degrade EPS matrix in pathogenic acidic bioﬁlms when
activated by H2O2. The Dex-NZM-mediated H2O2 catalysis can potently disrupt the development
of cariogenic biofilms and prevent localized demineralization and caries-like lesions on toothenamel surface. These results indicated that Dex-NZM, when used as a topical oral treatment,
would be selective for bioﬁlms over the host tissues in the oral cavity, impacting caries
development while sparing mammalian host cells in vivo.

3.6 In Vivo Inhibition of Dental Caries
The in vivo eﬃcacy of Dex-NZM as an anti-caries treatment was evaluated in a well-established
rodent model of dental caries52. In addition to mineralized tooth tissue, both the effects on soft
tissue and on the oral microbiota composition/diversity were examined. In this model, tooth
enamel progressively develops caries lesions (analogous to those observed in humans), proceeding
from initial areas of demineralization to moderate lesions and on to extensive (severe) lesions
characterized by enamel structure damage and cavitation. We simulated the treatment conditions
that might be experienced clinically in humans by applying the test agent solutions topically twice
daily with a brief, 1 min exposure time. We found that Dex-NZM/H2O2 treatment was highly
effective in reducing caries development in both smooth and sulcal surfaces (Figure 15a, b),
resulting in signiﬁcantly less overall caries lesions compared to vehicle control and Dex-NZM or
H2O2 alone. Importantly, the severity of caries lesions was progressively blocked and completely
prevented extensive lesions and cavitation on smooth dental surface. Furthermore, the eﬃcacy of
Dex-NZM/H2O2 was signiﬁcantly higher than H2O2 or Dex-NZM alone (Figure 15a, b), supporting
the catalytic-therapeutic mechanism of Dex-NZM activation of H2O2 via its intrinsic catalytic
activity.

In vivo data provided further validation of biocompatibility after 21 days of topical treatment via
analysis conducted on the gingival tissues and the oral microbiota. Histopathological analysis on
gingival and palatal tissues revealed no visible signs of adverse effects, such as proliferative
changes, inﬂammatory responses, or necrosis, of treatment with Dex-NZM, or H2O2 or the DexNZM/H2O2 (Figure 16a). This result supports our in vitro ﬁndings showing that Dex-NZM lacks
cytotoxic effects and more selectively binds to bacterial bioﬁlms rather than gingival epithelial
cells. The effects of Dex-NZM/H2O2 on oral microbiota were also evaluated, and no statistically
signiﬁcant changes of oral microbial composition and diversity were found between the treatment
groups (Figure 16b, c). Taken together, the data show that topical Dex-NZM/H2O2 treatments can
efﬁciently suppress the development of a costly and prevalent oral disease without affecting the
oral microbiota composition or showing deleterious effects in the surrounding soft tissues in vivo.

CHAPTER 4: DISCUSSION
We report herein that dextran-coated iron oxide nanozymes are an effective antibioﬁlm agent that
can be used for treatment of a ubiquitous oral disease, dental caries. The observation of catalytic
activity arising from coated iron oxide nanoparticles is important. Surface coating of nanozymes
can affect their enzyme-like activity, since binding of the coating to the nanoparticle reduces the
surface available to interact with substrates64,69. In biological applications of nanozymes, it is often
necessary to ﬁnd coatings that provide both stability in physiological ﬂuids as well as allow access
of substrates to the nanoparticle surface70.
We found that dextran coating did not silence the peroxidase-like activity of iron oxide
nanoparticles. This ﬁnding agrees with a previous report64, although the iron oxide nanoparticles
were more than 10-fold larger than in this study. It also agrees with previous reports of dextran
coating of iron oxide nanoparticles leaving gaps on their surfaces71. This property may play a role
in other bioactivities that have been observed to arise from iron oxide nanoparticles72,73. It may be
the case that this catalytic activity could be used against bioﬁlms in other settings such as joint
replacements or catheters. The eﬃcacy of the Dex-NZM/H2O2 combination may indicate that other
peroxidase mimics, such as graphene40, will have similar antibioﬁlm effects. In addition, the
bioﬁlm targeting effect that we found with dextran could potentially be used with other materials
such as gold nanoparticles74. The advantages of Dex-NZM are further highlighted by their
comparison with uncoated NZM. We found that uncoated NZM bind indiscriminately to bioﬁlms
and tissues in the mouth (i.e., they bound to mammalian cells and hydroxyapatite), whereas DexNZM bound more selectively to bioﬁlms. Moreover, we found that Dex-NZM were well
suspended in different solutions tested, while the uncoated NZM settled rapidly in each ﬂuid. The
settling of a formulation is a signiﬁcant drawback for practical consumer product development

since the dose might be dispensed unevenly, leading to reduced effectiveness in addition to
possible adverse effects due to unspeciﬁc binding.
Dex-NZM display peroxidase-like activity at pathological acidic pH values found in cariogenic
biofilms but attenuated at pH values close to neutral (physiological), avoiding unmitigated free
radical production. Dex-NZM retained within bioﬁlms can locally activate H2O2 for in situ
bacterial killing via membrane disruption and EPS matrix degradation through glucan structure
cleavage. Such properties thwarted cariogenic bioﬁlm accumulation and prevented enamel surface
damage, suppressing the onset of severe caries lesions, without deleterious side effects in vivo.
This therapeutic approach may have broader reach as EPS are important components of matrices
in most bioﬁlms2 and acidic pH microenvironments can be found in other pathological conditions,
such as in cystic ﬁbrosis and Staphylococcal infections75,76. Thus, exploitation of catalytic actions
by clinically approved nanomaterials could open up a new avenue for prevention of infectious
diseases.
Current antimicrobial approaches, including silver nanoparticles, chlorhexidine, hydrogen
peroxide, and other chemical biocides are incapable of degrading EPS and ineffective against
dental caries28,77. Fluoride, introduced over 60 years ago, as well as more recent nanoapatites can
reduce demineralization and promote remineralization but has limited antibioﬁlm effects28. We
have thus discovered a topical use of Dex-NZM to expand the few clinically available options for
caries-preventive therapy. Immediate clinical applications of Dex-NZM-mediated catalysis could
entail potentiating the efﬁcacy of existing peroxide-based modalities, including mouthrinses and
toothpastes, which contain 1.5-10% H2O2. Dex-NZM could be locally delivered using containers
with separate chambers that can keep the iron oxide nanoparticles and H2O2 separated in storage,
but allowing mixing at the time of product delivery (rising or brushing). In terms of dosage, the

rodent caries model has contributed to the development of clinically effective toothpastes and
related caries-preventive products, including assessment of optimal ﬂuoride concentration
{REF?}. Thus, the currently tested topical dosage may achieve therapeutic effects clinically,
although further optimization of Dex-NZM and H2O2 concentrations may be required to develop
a cost effective, safe and efﬁcacious treatment.
Dex-NZM might have applications for other oral diseases and against additional bacterial strains78;
however, this technology may have limitations when the local pH environment is not acidic (e.g.,
periodontal diseases) or with microoganisms that can degrade H2O2. Another potential drawback
is the possibility of iron staining of enamel. We found that Dex-NZM to bound poorly to salivacoated hydroxyapatite in vitro and minimally leached free irons even at acidic pH, and we did not
observe any discoloration over the 21-day period of the in vivo experiment. Nevertheless, more
extensive testing will be required to establish that Dex-NZM does not stain teeth in humans. Lastly,
lack of visualization of bioﬁlms on the teeth from the animal experiments and unavailability of
appropriate uncoated NZM control due to its aforementioned issues are experimental limitations
of this study. Further detailed analysis of the in vivo bioﬁlms following treatment and inclusion of
NZM control with inert non-dextran coatings in addition to dosage and treatment duration
optimization shall reveal important mechanistic insights as well as advance this catalytic
nanotherapeutic approach.
The iron-oxide-particle-based system has many inherent advantages over other nanoparticle-based
systems. It is a drugfree approach, thus overcoming limitations of drug dosing, requirement of
drug loading compatibilities, and risks associated with drug resistance. However, there are still
outstanding questions regarding the clinical translation of the approach, including potential oﬀtarget effects within the oral cavity and systemically for the Dex-NZM system and other

nanoparticle approaches. Nonspeciﬁc oﬀ-target effects of oral anti-bioﬁlm treatments can occur
both immediately to local tissues and after clearance of nanoparticles. The predominant clearance
route of topical treatments in the mouth is via ingestion, which may result in systemic circulation
and tissue distribution. Therefore, it is critical to evaluate potential oﬀ-target biodistribution and
effects prior to translation into new antibioﬁlm nanotechnologies. This point is especially true for
oral bioﬁlm therapies. Human caries affects all ages, and treatment is a persistent challenge. Thus,
chronic oﬀ-target accumulation of nanoparticles may result in long-lasting effects. Metal or metaloxide-based nanoparticles can be absorbed within the gastrointestinal tract. Although
bioavailability may be low (e.g., <5% of ingested dose), oﬀ-target systemic effects of nanoparticles
have been reported33. Metal nanoparticles with larger doses have resulted in weight loss and
increases in oxidative stress in blood, liver, brain, kidney, and spleen79, with long-term residence
in the brain80. In addition, tissue ﬁbrosis81,82 and DNA damage have been reported83. Although it
is unclear if iron oxide particles will have similar toxicity proﬁles, their likely transport through
the acidic stomach milieu, which will itself result in robust radical production, motivates careful
evaluation of systemic effects of this powerful oral bioﬁlm treatment strategy as well as other
nanoparticle-based approaches.
In summary, Dex-NZM is very stable in saliva or physiological buffers, does not bind to
mammalian cells, is retained within bacterial bioﬁlms, and is effective in reducing dental caries
without deleterious effects on the surrounding soft oral tissues. In addition, Dex-NZM/H2O2 does
not adversely affect oral microbiota diversity and composition. The translation of this treatment to
use in humans is likely practical, since the costs of the various reagents, such as iron salts and
hydrogen peroxide, are quite low and readily available. The treatment could be supplied as a
mouthwash with a bottle containing two chambers or in toothpaste form where the nanoparticles

and hydrogen peroxide are kept separate until the toothpaste is dispensed. It might be possible to
develop a formulation that self generates hydrogen peroxide, thereby circumventing the need for
two chambers in the container, although such an agent may be more complex and expensive.
Additional dosing and safety studies would have to be done before testing in humans; however,
the prior FDA-approval of similar iron oxide nanoparticles for systemic use (at several hundredfold higher dosage) and the limited exposure received via topical applications in the oral cavity
provide reasons to be optimistic about the safety of this approach. We also envision this therapeutic
approach to be particularly useful for patients with or at high risk of developing severe childhood
caries, an aggressive form of disease characterized by rampant tooth decay, that is often associated
with iron deﬁciency.
CONCLUSIONS
Dextran-coated iron oxide nanozymes are an effective antibioﬁlm agent for an oral disease.
Despite the dextran coating, these nanozymes possess peroxidase-like catalytic activity and have
additional attractive attributes such as stability and targeting speciﬁcity. Dex-NZM display
peroxidase-like activity at pathological acidic pH values, eﬃciently target bioﬁlm cells, and
degrade EPS matrix via catalytic activation of H2O2. Further analyses revealed that the catalytic
activity arises from the iron cores of these nanoparticles and that their dextran coating provides
selective binding to bacterial cells over oral epithelial cells while facilitating incorporation into
bioﬁlm matrix (Figure 17). In vivo results showed that Dex-NZM mediated H2O2 catalysis potently
disrupted the onset of a costly and highly prevalent oral bioﬁlm-associated infection (dental caries
or tooth decay). The nanozyme-based topical therapy markedly reduced the number and severity
of caries lesions compared to controls. Histological and microbiome analyses revealed no adverse
eﬀects on the surrounding host tissues and oral microbiota diversity in vivo, consistent with lack

of cytotoxicity and bioﬁlm-targeting speciﬁcity observed in vitro. Altogether, Dex-NZM is a
potent and biocompatible antibioﬁlm agent. There are limitations of this technology, such as when
the local pH environment is not acidic or against bacterial strains that can degrade H2O2, while the
potential of tooth staining and in-depth safety studies need to be conducted and assessed.
Nevertheless, given the prior FDA-approval of similar agents, this nanozyme-based approach
could provide an excellent therapeutic platform for alternative product development to prevent the
burdensome of dental caries. At the same time, the availability and low cost of the materials and
chemical ﬂexibility of iron oxide nanoparticles could galvanize a wider investigation of this
approach for clinical applications to treat other bioﬁlm-related maladies.
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